NEUP
Neuphoria Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$3.77
+0.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (10.5M) | 15.6M | — | — | 383.2K |
| Cost of Revenue | 828.4K | 662.9K | 663.0K | 671.5K | 16.0M |
| Gross Profit | (11.0M) | 15.0M | (663.0K) | (671.5K) | (10.0M) |
| Operating Expenses | |||||
| R&D Expense | 6.7M | 9.0M | 14.1M | 19.7M | 23.3M |
| SG&A Expense | 7.2M | 7.8M | 8.5M | 13.4M | 7.7M |
| General & Admin Expense | 7.2M | 7.8M | 8.5M | 13.4M | 7.4M |
| Selling & Marketing Expense | — | — | — | — | 262.4K |
| Other Expenses | 16.8B | (662.9K) | (4.7M) | — | (7.2M) |
| Total Operating Expenses | 16.8B | 16.1M | 17.9M | 33.1M | 23.7M |
| Cost and Expenses | 16.8B | 16.8M | 17.9M | 33.1M | 39.8M |
| Operating Income (EBIT) | (24.2M) | (1.1M) | (26.8M) | (33.1M) | (31.0M) |
| Non-Operating | |||||
| Interest Income | 582.5K | 166.5K | 220.1K | 486.4K | 9.9K |
| Interest Expense | — | — | — | — | 26.9K |
| Net Interest Income | 582.5K | 166.5K | 220.1K | 486.4K | (17.0K) |
| Other Non-Op Income/Expense | (4.6M) | 291.1K | 2.3M | 695.5K | (886.0K) |
| Non-Operating Income (excl Interest) | (2.6M) | — | (142.5K) | (636.3K) | 847.0K |
| EBT (Pre-Tax Income) | (28.8M) | (838.0K) | (15.6M) | (32.4M) | (31.9M) |
| Income Tax Expense | (279.1K) | (468.4K) | (87.3K) | (209.5K) | (278.8K) |
| Bottom Line | |||||
| Net Income | (28.5M) | (369.6K) | (15.5M) | (32.2M) | (22.9M) |
| Earnings from Cont. Ops | (28.5M) | (369.6K) | (15.5M) | (32.2M) | (22.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (22.1M) | (369.6K) | (15.5M) | (32.2M) | (22.9M) |
| Per Share | |||||
| Basic EPS | ($11.00) | ($0.23) | ($0.10) | ($0.24) | ($0.20) |
| Diluted EPS | ($11.00) | ($0.23) | ($0.10) | ($0.24) | ($0.20) |
| Revenue Per Share | ($1.94) | $9.64 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.4M | 1.6M | 149.8M | 122.4M | 112.8M |
| Diluted Shares Outstanding | 5.4M | 1.6M | 149.8M | 122.4M | 112.8M |
| Profitability Metrics | |||||
| EBITDA | (22.7M) | (121.9K) | (25.7M) | (31.5M) | (30.3M) |
| D&A | 883.4K | 1.0M | 992.6K | 998.2K | 1.6M |
| EBIT | (23.6M) | (1.1M) | (26.6M) | (32.5M) | (31.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026